Refine by
Cytokine Software
6 software items found
by:Progentec Diagnostics, Inc. based inOklahoma City, OKLAHOMA (USA)
Immunological insights for proactive lupus care; Get started today with aiSLE DX Flare Risk Index, a new blood test that identifies a SLE patient's future risk of a lupus ...
by:Longeveron, Inc. based inMiami, FLORIDA (USA)
We are conducting a multicenter, double-blinded, randomized, placebo-controlled trial for ARDS due to COVID-19 or influenza virus infection. ARDS can be rapidly induced by a variety of insults, such as coronavirus and influenza virus infection. Approximately 150,000 people experience ARDS in the U.S. annually, with a mortality rate of about 40%. These numbers are increasing as a result of ...
by:Certara based inPrinceton, NEW JERSEY (USA)
Biological medicines (“biologics” or “large molecule drugs”) now account for 30% of new drug approvals and up to 50% of the pharmaceutical industry’s pipeline. Biologics differ from small molecules because they are much larger, have slower absorption rates, confined distribution, and different elimination. They are designed for a specific target, typically found on ...
by:Progentec Diagnostics, Inc. based inOklahoma City, OKLAHOMA (USA)
aiSLE MGMT is a lupus management platform that provides clinicians with unparalleled insight into lupus disease activity and the patient's experience. It combines two new technologies -- both powered by artificial ...
by:Cypre, Inc. based inSan Francisco, CALIFORNIA (USA)
Cypre’s 3D Tumor Models combine the tumor, stromal and immune compartments in a high throughput format to screen targeted drugs and immunotherapy. In 2021, we partnered with Charles River to offer our 3D Tumor Models for drug discovery and preclinical screening services. Cypre Panels rapidly screen small molecules, biologics and cell therapy in 3D hydrogel in vitro tumor models. ...
by:Certara based inPrinceton, NEW JERSEY (USA)
The Simcyp Simulator is the pharmaceutical industry’s most sophisticated physiologically based pharmacokinetics (PBPK) platform for determining first-in-human dosing, optimizing clinical study design, evaluating new drug formulations, setting the dose in untested populations, performing virtual bioequivalence analyses, and predicting drug-drug interactions (DDIs). Simcyp is being applied to ...